...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Back to the draw­ing board for triple-neg­a­tive breast can­cer tar­gets, re­searchers pro­pose new com­bo ap­proach.
Reply New Message
Back To Forum List View
Back to the draw­ing board for triple-neg­a­tive breast can­cer tar­gets, re­searchers pro­pose new com­bo ap­proach.
5
10-41
Mar 28, 2020 06:13PM
Re: Back to the draw­ing board for triple-neg­a­tive breast can­cer tar­gets, re­searchers pro­pose new com­bo ap­proach.
7
narmac
Mar 31, 2020 02:23PM

Had a conversation with mgmt a couple of months ago 're Rv x and asked about Zenith was told the Breast trial after a Late start was showing great results and that the Prostate trial was to be presented at end of April...that conference is cal  I had PM to a poster at that time  as most were only interested in Rvx

4 Recommendations
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply